Cat. No. | Product name | CAS No. |
DC47225 |
AS-99 TFA
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo. |
|
DC47262 |
MRTX9768 hydrochloride
MRTX9768 hydrochloride is a potent, orally active PRMT5 inhibitor. MRTX9768 hydrochloride is a synthetic lethal-based inhibitor binding the PRMT5-MTA complex. |
|
DC47264 |
MS67
MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects. |
2407452-77-9 |
DC47608 |
EZH2-IN-2
EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity. |
2238821-31-1 |
DC47609 |
PRMT1-IN-1
PRMT1-IN-1 is a PRMT1 inhibitor. |
1025948-98-4 |
DC47610 |
PRMT5-IN-3
PRMT5-IN-3 is a PRMT5 inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents. |
2159123-14-3 |
DC47611 |
PRMT5-IN-14
PRMT5-IN-14 is a PRMT5 inhibitor to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations. |
2278356-90-2 |
DC47612 |
PRMT5-IN-11
PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range. |
2567564-33-2 |
DC47613 |
PRMT5-IN-12
PRMT5-IN-12 shows remarkable inhibitory activity on PRMT5. |
2568927-94-4 |
DC47614 |
EEDi-5273
Featured
EEDi-5273 is an exceptionally potent and orally efficacious embryonic ectoderm development (EED) inhibitor with IC50 of 0.2 nM and inhibits the KARPAS422 cell growth with IC50 of 1.2 nM. EEDi-5273 demonstrates an excellent PK and ADME profile, and its oral administration leads to complete and persistent tumor regression in the KARPAS422 xenograft model with no signs of toxicity. |
2585648-55-9 |
DC47615 |
PRMT5-IN-9
PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM. |
2691869-52-8 |
DC47616 |
EPZ-719
Featured
EPZ-719 is a novel and potent SETD2 inhibitor ( IC50 = 0.005 μM) with a high selectivity over other histone methyltransferases. |
2697176-16-0 |
DC47617 |
EED ligand 1
EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase. |
|
DC47618 |
PRMT5-IN-10
PRMT5-IN-10 has promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex. |
2567564-23-0 |
DC47943 |
MS33
MS33 is a potent WDR5 degrader, with Kds of 870 nM and 120 nM for VCB and WDR5, respectively. MS33 induces WDR5 degradation in an E3 ligase VHL, and proteasome-dependent manner. MS33 can be used for the research of acute myeloid leukemia. |
2407449-11-8 |
DC48009 |
DCLX069
DCLX069 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 value of 17.9 µM. DCLX069 shows less active against PRMT4 and PRMT6. DCLX069 has anticancer effects. |
792946-69-1 |
DC48412 |
CPI-1328
CPI-1328 is an EZH2 inhibitor with a Ki value of 63 fM. |
2390367-27-6 |
DC48413 |
PRMT5-IN-15
PRMT5-IN-15 is a PRMT5 inhibitor with an IC50 value of 0.84 nM. |
2410637-87-3 |
DC48414 |
EZH2-IN-6
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity. |
2702269-27-8 |
DC50233 |
(S)-HH2853
(S)-HH2853 (compound 200), a PYRIDINO five membered aromatic ring compound, is a potent EZH1/2 dual inhibitor with an IC50 of <100 nM for EZH2_Y641F. (S)-HH2853 has the potential to be used in the research of anti-tumor or autoimmune diseases. |
2202678-05-3 |
DC50234 |
(R)-HH2853
(R)-HH2853 is a mutant EZH2 inhibitor with an IC50 of <100 nM for EZH2-Y641F. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201). |
2202678-06-4 |
DC50236 |
MC4355
MC4355 is a dual inhibitor of EZH2 and histone deacetylase (HDAC). |